Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Ciro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, Salvatore Battaglia, Marco Enea, Bernhard Scheiner, Antonio D’Alessio, Giulia Francesca Manfredi, Bernardo Stefanini, Naoshi Nishida, Peter R. Galle, Kornelius Schulze, Henning Wege, Roberta Ciccia, Wei‐Fan Hsu, Caterina Vivaldi, Brooke Wietharn, Ryan Po-Ting Lin, Angelo Pirozzi, Tiziana Pressiani, Andrea Dalbeni, L.A. Natola, A. Auriemma, Cristina Rigamonti, Michela Emma Burlone, Alessandro Parisi, Yi‐Hsiang Huang, Pei‐Chang Lee, Celina Ang, Thomas U. Marron, Matthias Pinter, Jaekyung Cheon, Samuel Phen, Amit G. Singal, Anuhya Gampa, Anjana Pillai, Natascha Roehlen, Robert Thimme, Arndt Vogel, Noha Soror, Susanna V. Ulahannan, Rohini Sharma, David Sacerdoti, Mario Pirisi, Lorenza Rimassa, Chung‐Yen Lin, Anwaar Saeed, Gianluca Masi, Martin Schönlein, Johann von Felden, Masatoshi Kudo, Alessio Cortellini, Hong Jae Chon, Calogero Cammà, David J. Pinato
Abstract
BACKGROUND AND AIMS: Unlike other malignancies, hepatic functional reserve competes with tumor progression in determining the risk of mortality from hepatocellular carcinoma (HCC). However, the relative contribution of hepatic decompensation over tumor progression in influencing overall survival (OS) has not been assessed in combination immunotherapy recipients. APPROACH AND RESULTS: From the AB-real observational study (n = 898), we accrued 571 patients with advanced/unresectable hepatocellular carcinoma, Child-Pugh A class treated with frontline atezolizumab + bevacizumab (AB). Hepatic decompensation and tumor progression during follow-up were studied in relationship to patients' OS using a time-dependent Cox model. Baseline characteristics were evaluated as predictors of decompensation in competing risks analysis. During a median follow-up of 11.0 months (95% CI: 5.1-19.7), 293 patients (51.3%) developed tumor progression without decompensation, and 94 (16.5%) developed decompensation. In multivariable time-dependent analysis, decompensation (HR: 19.04, 95% CI: 9.75-37.19), hepatocellular carcinoma progression (HR: 9.91, 95% CI: 5.85-16.78), albumin-bilirubin (ALBI) grade 2/3 (HR: 2.16, 95% CI: 1.69-2.77), and number of nodules >3(HR: 1.63, 95% CI: 1.28-2.08) were independently associated with OS. Pretreatment ALBI grade 2/3 (subdistribution hazard ratio [sHR]: 3.35, 95% CI: 1.98-5.67) was independently associated with decompensation, whereas viral etiology was protective (sHR: 0.55, 95% CI: 0.34-0.87). Among patients with viral etiology, effective antiviral treatment was significantly associated with a lower risk of decompensation (sHR: 0.48, 95% CI: 0.25-0.93). CONCLUSIONS: Hepatic decompensation identifies patients with the worst prognosis following AB and is more common in patients with baseline ALBI >1 and nonviral etiology. Effective antiviral treatment may protect from decompensation, highlighting the prognostic disadvantage of patients with nonviral etiologies and the importance of multidisciplinary management to maximize OS.